Michael Shleifer
Managing Partner & Co-Founder @ SPRIM
Michael Shleifer is a Series A investor at SPRIM focused on Biotechnology and Health Care. Dr. Michael Shleifer is the Founder and Managing Partner of SPRIM, as well as the Co-Founder of SPRIM Ventures.
- Total investments:
- 4
- Last investment:
- Lead investor:
- 75%
Last updated:
For AI agents: llms.txt
Industries Michael Shleifer invests in
Stages Michael Shleifer invests in
Countries Michael Shleifer invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 3 (75%)
- Health Care 2 (50%)
- Medical Device 2 (50%)
- Oncology 1 (25%)
- Biopharma 1 (25%)
Stage
- Series A 2 (50%)
- Seed 1 (25%)
- Series D 1 (25%)
Country
- Australia 2 (50%)
- France 1 (25%)
- United States 1 (25%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
NinaMED
|
NinaMED is a healthcare and medical solutions company associated with medical services and technology-enabled healthcare solutions. | $10M / Seed / May 13, 2026 | |
ErVimmune
|
ErVimmune creates novel immunotherapies that target non-conventional tumor antigens that are abnormally expressed in cancer cells and shared by tumors and patients, with a particular emphasis on meeting unmet medical requirements in cold malignancies. | $19.9M / Series A / Jan 21, 2026 | |
Vaxxas
|
Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia. | $31.8M / Series D / Aug 25, 2025 | |
Doron Therapeutics
|
Doron Therapeutics is a clinical-stage biotechnology company that has developed intra-articular biologic drugs derived from placental tissue and consistently delivers a host of beneficial growth factors with potent anti-inflammatory, tissue-protective, and regenerative capabilities pivotal to the progressive and degenerative disease ofosteoarthritis. | $11M / Series A / Nov 25, 2024 |
Co-Investors
About SPRIM
SPRIM is a management consulting company with a venture capital division, known as SPRIM Ventures.
SPRIM Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Dan Brenner
Chief Growth Officer
|
|||
Ivan Jarry
Co-Founder & Managing Partner
|
|||
|
Michael Shleifer
Managing Partner & Co-Founder
|
|||
Olivier Shleifer
Co-Founder & Managing Partner
|
|||
|
Rodney Cheung
CIO
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Michael Shleifer invest in?
Michael Shleifer invests primarily in Biotechnology, Health Care and Medical Device startups, most often at Series A and Seed stage. Most of the 4 investments tracked by Shizune back companies in Australia. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Michael Shleifer?
Public channels for Michael Shleifer include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Michael Shleifer last invest?
The most recent investment recorded for Michael Shleifer closed in May 2026. Shizune tracks 4 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
